Paul Hartmann Valuation
Is PHH2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PHH2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PHH2 (€209) is trading below our estimate of fair value (€6611.33)
Significantly Below Fair Value: PHH2 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PHH2?
Key metric: As PHH2 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is PHH2's PE Ratio? | |
|---|---|
| PE Ratio | 12.5x |
| Earnings | €59.53m |
| Market Cap | €742.31m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.5x |
| Enterprise Value/EBITDA | 7.6x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does PHH2's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 19.5x | ||
DRW3 Drägerwerk KGaA | 7.2x | 2.0% | €796.1m |
EUZ Eckert & Ziegler | 23.2x | 5.9% | €831.3m |
COP CompuGroup Medical SE KGaA | 28.9x | 32.9% | €726.9m |
RHK RHÖN-KLINIKUM | 18.6x | 7.5% | €836.7m |
PHH2 Paul Hartmann | 12.5x | n/a | €742.3m |
Price-To-Earnings vs Peers: PHH2 is good value based on its Price-To-Earnings Ratio (12.5x) compared to the peer average (19.5x).
Price to Earnings Ratio vs Industry
How does PHH2's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: PHH2 is good value based on its Price-To-Earnings Ratio (12.5x) compared to the European Medical Equipment industry average (29.5x).
Price to Earnings Ratio vs Fair Ratio
What is PHH2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 12.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PHH2's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
LNA Santé
€244.4m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.1%
1Y
16.0%
Shandong Weigao Group Medical Polymer
HK$20.1b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-1.0%
1Y
-38.8%
OrbusNeich Medical Group Holdings
HK$3.4b
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
Q8T
HK$0.51
7D
12.2%
1Y
-43.3%